CDC encourages 16-and-17-year-old adolescents to receive COVID-19 booster shot

Editorial Checklist Reviewed

The following is attributable to CDC Director, Dr. Rochelle Walensky

"Today, CDC is strengthening its booster recommendations and encouraging everyone 16 and older to receive a booster shot. Although we don't have all the answers on the Omicron variant, initial data suggests that COVID-19 boosters help broaden and strengthen the protection against Omicron and other variants. We know that COVID-19 vaccines are safe and effective, and I strongly encourage adolescents ages 16 and 17 to get their booster if they are at least 6 months post their initial Pfizer vaccination series."

At this time, only the Pfizer-BioNTech COVID-19 vaccine is authorized and recommended for adolescents aged 16 and 17. More information will be available on CDC's website soon.

Source:

Centers for Disease Control and Prevention

Posted in: Child Health News | Healthcare News

Tags: , , , , ,

Comments (0)

Suggested Reading

Limited impact of prenatal COVID-19 exposure on child neurodevelopmental outcomes
COVID-19 raises the risk of type 2 diabetes in children, study reveals
Masks and smart seating cut COVID-19 risks on flights, review finds
Link between COVID-19 and long-term risk of autoimmune and autoinflammatory connective tissue disorders
Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients
Could vitamin D help COVID-19 patients? Meta-analysis highlights potential ICU reduction
Mucosal COVID-19 boosters outperform mRNA shots in preventing upper airway infections
New study reveals long-term brainstem damage in COVID-19 survivors using advanced MRI scans

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Study finds nirmatrelvir-ritonavir reduces severe COVID-19 and long COVID risks in high-risk patients